Vitex suspends trial for pathogen inactivation system
This article was originally published in Clinica
VI Technologies (Vitex) has suspended a phase III study of its Inactine blood pathogen inactivation system, after one of the patients in the trial developed an immune response to cells treated with the technology. The company said that pending further evaluation with the US FDA, no additional patients would be recruited to the study. Inactine is designed to inactivate viruses, bacteria and parasites in red blood cells.
You may also be interested in...
Office of New Drugs Director Peter Stein said in an interview that a large amount of coronavirus-related work is arriving at the FDA, but so far staff are keeping up.
Akero’s FGF21 analog yields 63%-72% relative hepatic fat reduction in Phase IIa study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says COVID-19 pandemic should not significantly delay its Phase III NASH readout.
US Vice President Mike Pence and Medicare administrator Seema Verma want academic and university hospital laboratories to send their de-identified COVID-19 test data results, daily, to the Department of Health and Human Services. Commercial and private labs are exempt from the request, as they already share their coronavirus test results with the government.